Calliope Maris
Overview
Explore the profile of Calliope Maris including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
29
Citations
458
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Racu M, Schiavo A, Van Campenhout C, De Neve N, Masuy T, Maris C, et al.
Exp Mol Pathol
. 2024 Jul;
139:104920.
PMID: 39033589
Pancreatic ductal adenocarcinoma (PDAC) is reported to be amongst the cancers with the lowest survival rate at 5 years. In the present study we aimed to validate a targeted next-generation...
2.
DHaene N, Sauvage S, Maris C, Adanja I, Mercier M, Decaestecker C, et al.
PLoS One
. 2023 Dec;
18(12):e0295736.
PMID: 38060508
[This corrects the article DOI: 10.1371/journal.pone.0067029.].
3.
Racu M, Bernardi D, Chaouche A, Zindy E, Navez J, Loi P, et al.
Cancers (Basel)
. 2023 Aug;
15(15).
PMID: 37568581
Background: SMAD4 is inactivated in 50-55% of pancreatic ductal adenocarcinomas (PDACs). SMAD4 loss of expression has been described as a negative prognostic factor in PDAC associated with an increased rate...
4.
Demols A, Rocq L, Perez-Casanova L, Charry M, De Neve N, Ramadhan A, et al.
Oncologist
. 2023 Mar;
28(7):e520-e525.
PMID: 36994874
Background: It is of interest to determine the incidence and molecular characteristics of NTRK gene fusions in patients with bilio-pancreatic cancers, because of possible treatment with TRK inhibitors for advanced...
5.
Racu M, Lebrun L, Schiavo A, Van Campenhout C, De Clercq S, Absil L, et al.
Cancers (Basel)
. 2022 Feb;
14(4).
PMID: 35205719
Pancreatic ductal adenocarcinoma (PDAC) presents a five-year survival rate of 10% and its incidence increases over the years. It is, therefore, essential to improve our understanding of the molecular mechanisms...
6.
Verocq C, Racu M, Bafort D, Butorano G, Perez-Casanova Garcia L, Navez J, et al.
Diagn Pathol
. 2021 Dec;
16(1):117.
PMID: 34895278
Background: Pancreatic medullary carcinoma (PMC) is a rare pancreatic tumor, usually showing the presence of microsatellite instability, mostly MLH1 silencing, and a wild-type KRAS mutation status. We report here a...
7.
Rusu S, Verocq C, Trepant A, Maris C, De Neve N, Blanchard O, et al.
Mol Clin Oncol
. 2021 Nov;
15(6):270.
PMID: 34790354
Metastatic melanoma is a fatal disease with poor prognosis. Ever since targeted therapy against oncogenic was approved, molecular profiling has become an integral part of the management of such patients....
8.
Koopmansch C, Noel J, Maris C, Simon P, Sy M, Catteau X
Breast Cancer (Auckl)
. 2021 Apr;
15:1178223421993459.
PMID: 33854326
Background: The challenge of breast-conserving surgery (BCS) is to remove the entire tumour with free margins and avoid secondary excision that may adversely affect the cosmetic outcome. Consequently, intraoperative evaluation...
9.
Catteau X, Koopmansch C, Maris C, Colart P, Noel J
Ann Diagn Pathol
. 2020 Sep;
49:151607.
PMID: 32949894
Recently, several trials demonstrated the safety of omitting axillary lymph node dissection in clinically N0 patients with positive sentinel nodes in select subgroups. However, this fact is still troublesome to...
10.
Remmelink M, De Mendonca R, DHaene N, De Clercq S, Verocq C, Lebrun L, et al.
Crit Care
. 2020 Aug;
24(1):495.
PMID: 32787909
Background: Post-mortem studies can provide important information for understanding new diseases and small autopsy case series have already reported different findings in COVID-19 patients. Methods: We evaluated whether some specific...